Clinical trials: Diabetes Type II
Heart Failure, Chronic Kidney Disease
Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease
The purpose of the study is to evaluate the efficacy and safety of AZD9977 in combination with dapagliflozin compared with dapagliflozin alone and to assess the dose-response relationship, dapagliflozin alone and 3 doses of…
- Trial name
- MIRACLE (NCT04595370)
- Testing
- AZD9977, Dapagliflozin
- Where
- 156 sites in United States, Belgium and 20 more
- Volunteers
- 153 people
- Sponsor
- AstraZeneca
CKD, Diabetes Mellitus, Type 2
The ORTIZ Study: Optimising RASi Therapy With SZC
The hypothesis is that 3 months' treatment with SZC versus placebo will enable RASi (Irbesartan) maximisation in a cohort of patients with diabetic kidney disease.
- Conditions
- CKD, Diabetes Mellitus, Type 2, Hyperkalemia
- Trial name
- ORTIZ (NCT04983979)
- Testing
- Sodium Zirconium Cyclosilicate
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Barts & The London NHS Trust
Type 2 Diabetes Mellitus
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
This is a study to evaluate the efficacy and safety of ertugliflozin (MK-8835/PF-04971729) in combination with sitagliptin in the treatment of participants with Type 2 diabetes mellitus (T2DM) with inadequate glycemic control on…
- Trial name
- NCT02226003
- Testing
- Ertugliflozin, Sitagliptin, Glimepiride
- Volunteers
- 291 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients
The objective of this study is to investigate the effect of BI 1356 on 24-h glucose control and various pharmacodynamic parameters in type 2 diabetic patients with inadequate glycaemic control.
- Trial name
- NCT00716092
- Testing
- Sitagliptin, Linagliptin
- Where
- 3 sites in Germany
- Volunteers
- 121 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)
This study will assess the effect of sitagliptin/metformin FDC 50/1000 mg (Janumet®), MK-0431A) compared with the effect of glimepiride on hemoglobin A1c (HbA1c).
- Trial name
- NCT00993187
- Testing
- Sitagliptin/Metformin FDC, Comparator: Glimepiride
- Volunteers
- 292 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.
- Trial name
- SURPASS-SWITCH (NCT05564039)
- Testing
- Tirzepatide, Dulaglutide
- Where
- 38 sites in United States, Belgium and 3 more
- Volunteers
- 282 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension
The purpose of Study BCB111 is to collect efficacy, pharmacokinetic, pharmacodynamic, safety, and tolerability data in patients with type 2 diabetes to assess the feasibility of once monthly dosing of the exenatide suspension…
- Trial name
- NCT01104701
- Testing
- exenatide once weekly, exenatide once monthly suspension
- Where
- 2 sites in United States
- Volunteers
- 121 people
- Sponsor
- AstraZeneca
Overweight and Obesity, Eating Behavior
Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM
The current project applies an integrative three-prong approach to investigate the potential of the dopamine D2 receptor (DRD2) agonist bromocriptine to: 1) increase homeostatic satiation signaling, 2) alter neural circuitry to…
- Trial name
- NCT05405244
- Testing
- Bromocriptine-QR
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Type 2 Diabetes Mellitus
Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to examine the participant's preference for treatment with once-weekly dosing of DPP-4 inhibitor trelagliptin versus once-daily dosing of DPP-4 inhibitor alogliptin among the participants with type 2…
- Trial name
- TRINITY (NCT03231709)
- Testing
- Trelagliptin, Alogliptin
- Where
- 2 sites in Japan
- Volunteers
- 60 people
- Sponsor
- Takeda
Hypercholesterolemia With Concomitant Type 2 Diabetes
LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts
The purpose of this study is to compare the effect of rosuvastatin and atorvastatin on lipid lowering effect and glucose metabolism in hypercholesterolemia patients with diabetes mellitus.
- Trial name
- LISTEN (NCT01544309)
- Testing
- Atorvastatin, Rosuvastatin
- Where
- 133 sites in Japan
- Volunteers
- 1,049 people
- Sponsor
- Listen Trial Group
Diabetes Type 2
Changing the Healthcare Delivery Model
This is a randomized controlled trial comparing 3 strategies to improve wellness behaviors and clinical goals for diabetes type 2(DM2) Medicaid patients.
- Trial name
- C4H (NCT02093234)
- Testing
- mobile health care application, CHWs and mobile health care application, Community Health Worker (CHW)
- Where
- United States
- Volunteers
- 166 people
- Sponsor
- George Washington University
Type 2 Diabetes, T2D
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)
The main purpose of this study is to determine the efficacy and safety of insulin efsitora alfa (LY3209590) administered weekly using a fixed dose escalation compared to insulin glargine in adults with type 2 diabetes (T2D) who…
- Trial name
- QWINT-1 (NCT05662332)
- Testing
- Insulin Efsitora Alfa, Insulin Glargine
- Where
- 71 sites in United States, Argentina and 2 more
- Volunteers
- 795 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus
The purpose of the study was to assess the effect of LIK066 on intestinal glucose absorption immediately after a single dose (immediate effect) and 6 hours following the dose (after multiple daily doses; sustained effect) in…
- Trial name
- NCT01915849
- Testing
- LIK066
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)
This study will compare the effects of commercially manufactured exenatide once weekly and exenatide BID in subjects whose type 2 diabetes is managed with diet and exercise alone or with oral antidiabetic medications.
- Trial name
- NCT00877890
- Testing
- exenatide once weekly, exenatide twice daily
- Where
- 41 sites in United States
- Volunteers
- 254 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in combination with basal insulin in patients…
- Trial name
- NCT01011868
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 99 sites in United States, Denmark and 5 more
- Volunteers
- 494 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetic Peripheral Neuropathy (DPN)
Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN)
The purpose of this research study is to determine if Metanx improves sensory neuropathy in persons with Type 2 diabetes. Metanx is a medical food available with a prescription from a physician.
- Trial name
- NCT00726713
- Testing
- Metanx (a medical food)
- Where
- 6 sites in United States
- Volunteers
- 214 people
- Sponsor
- Pamlab, Inc.
Diabetes, Diabetes Mellitus, Type 2
Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes
This trial is conducted in Asia, South America and the United States of America (USA). The aim of this clinical trial is to determine whether two insulin treatments given once daily are equally effective with respect to the blood…
- Trial name
- EFFICACY (NCT00909480)
- Testing
- insulin detemir, insulin glargine
- Where
- 88 sites in United States, Argentina and 4 more
- Volunteers
- 457 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i (sodium-glucose…
- Trial name
- DUALTM IX (NCT02773368)
- Testing
- insulin degludec/liraglutide, insulin glargine
- Where
- 88 sites in United States, Argentina and 9 more
- Volunteers
- 420 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 2 With Hyperglycemia
Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus
A 4-month, randomized, prospective, open-label comparison trial of hydroxychloroquine vs. pioglitazone in type 2 diabetic patients inadequately controlled on maximally tolerated doses of metformin plus a sulfonylurea.
- Trial name
- NCT02303405
- Testing
- Hydroxychloroquine, Pioglitazone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Charles Drew University of Medicine and Science
Diabetes Mellitus, Type 2
Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design
The objective of the randomised part of the study is to investigate the efficacy and safety of BI 1356 plus metformin compared to BI 1356 or metformin alone given for 24 weeks to drug naive or previously treated (4 weeks…
- Trial name
- NCT00798161
- Testing
- BI 1356, BI 1356 + metformin, Metformin
- Where
- 138 sites in Canada, Croatia and 12 more
- Volunteers
- 857 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.